StockData
BHVNNYSEPharmaceutical PreparationsFiscal year ends December 31

Biohaven Ltd.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$11.35+0.57 (+5.29%)

Close on Oct 19, 2026

Market cap
$1.71B
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Nov 9, 2026, before market open (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 10, 2026After market close–$-0.91$-0.78
Q1 FY2026
Ended Mar 31, 2026
May 4, 2026After market close–$-0.88$-0.69
Q4 FY2025
Ended Dec 31, 2025
Mar 2, 2026After market close–$-1.21$-0.90
Q3 FY2025
Ended Sep 30, 2025
Nov 10, 2025Before market open–$-1.64$-1.47
Q2 FY2025
Ended Jun 30, 2025
Aug 11, 2025After market close–––
Q1 FY2025
Ended Mar 31, 2025
May 12, 2025After market close–$-2.17$-1.64
Q4 FY2024
Ended Dec 31, 2024
Mar 3, 2025After market close–$1.85$1.71
Q3 FY2024
Ended Sep 30, 2024
Nov 12, 2024After market close–$-1.70$-1.74
Q2 FY2024
Ended Jun 30, 2024
Aug 8, 2024After market close–$-3.64$-3.50
Q1 FY2024
Ended Mar 31, 2024
May 9, 2024After market close–$-2.20$-1.77
Q4 FY2023
Ended Dec 31, 2023
Feb 29, 2024After market close–$-1.81$-1.61

Press releases

Announcements Biohaven filed with the SEC